Latigo Biotherapeutics Inc.

LTGO

NASDAQHealthcareMedical - Pharmaceuticals

在 GoAI 中打开

收盘时

US$14.04

−US$0.53 · -3.64%

11月4日 16:00 ET

公司概况

公司网站

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.

行业: Medical - Pharmaceuticals
部门: Healthcare
总部: US
首席执行官: Nima Farzan
上市以来: 2026年8月7日
雇员: 66

市场位置

日内区间

当前US$14.04

US$13.95US$15.00

52周区间

当前US$14.04

US$13.26US$25.93

开盘价: US$14.87
前收盘价: US$14.57
成交量: 15.59万; 0.46× 平均值
平均成交量: 33.61万; 日均成交量
市值: 8.45亿 USD
贝塔: 0; 市场参考 1
50天平均值: US$18.5926; 低于平均水平-24.49%
200天平均值: US$18.8694; 低于平均水平-25.59%

分析师评级

第三方分析师预期可能变化，并非 GoAI 建议。

分析师目标价

平均目标

US$52.25

上涨空间 272.15%

过去 12 个月12个月预测最高：US$73.00平均的：US$52.25最低：US$36.00

LTGO 消息

globenewswire.com2026年11月3日

Latigo Biotherapeutics to Participate in Upcoming Investor Conferences in November

THOUSAND OAKS, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Latigo Biotherapeutics, Inc. (Nasdaq: LTGO), a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines, today…

阅读源码

seekingalpha.com2026年10月11日

Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From It

Latigo Biotherapeutics is undervalued below IPO, with onzotrigine showing superior efficacy to Vertex's Journavx in acute pain. LTGO leverages Vertex's market groundwork, has pivotal-eligible Phase 2 data, and is funded…

阅读源码

defenseworld.net2026年10月8日

Latigo Biotherapeutics (NASDAQ:LTGO) Hits New 12-Month Low – Here’s Why

Latigo Biotherapeutics, Inc. (NASDAQ: LTGO - Get Free Report) shares hit a new 52-week low on Thursday. The stock traded as low as $15.27 and last traded at $15.52, with a volume of 241512 shares trading hands. The stock…

阅读源码

defenseworld.net2026年9月9日

Latigo Biotherapeutics, Inc.’s Quiet Period Will End on September 16th (NASDAQ:LTGO)

Latigo Biotherapeutics' (NASDAQ: LTGO - Get Free Report) quiet period will expire on Wednesday, September 16th. Latigo Biotherapeutics had issued 19,200,000 shares in its public offering on August 7th. The total size of…

阅读源码

globenewswire.com2026年9月3日

Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Completed upsized initial public offering, including full exercise of the underwriters' option to purchase additional shares, raising gross proceeds of $397.4 million; together with existing cash expected to fund…

阅读源码